Responses
Cardiovascular medicine
Protocol
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)
Compose a Response to This Article
Other responses
No responses have been published for this article.